Charcot-Marie-Tooth type 1a is an orphan genetic progressive de/dysmyelinating peripheral neuropathy affecting 125 000 persons across US and Europe. Disease, although clinically heterogeneous, impairs and quite often
legislation that allowed a drug to be designated an orphan on the basis of rarity of the disease, a plausible mechanism of action, and likelihood of benefit Of 255 applications ... where between 1983 and 2002 nearly…
Drugs” to enhance and explore knowledge among academics and industry personnel dealing with Rare Disease, Orphan Drug, and its related subjects to establish corporations and exchange ideas. Rare Disease ... core…
Charcot-Marie-Tooth type 1a is an orphan genetic progressive dys/demyelinating peripheral neuropathy affecting 125000 persons across Europe and US Disease, although clinically heterogeneous, impairs and very often badly
Pluripotent stem cells represent a potential regenerative medicine for several orphan diseases because the cells exhibit broad plasticity. Induced pluripotent stem cells (IPSC) have the potential to serve…
cells (IPSC) are excellent patient-specific stem cells for phenotypic drug screening platforms for orphan disease. Disease-specific IPSC has the advantage over prior conventional approaches to better predict drug…
Rare genetic disorders, also known as orphan diseases, pose significant challenges in terms of diagnosis and treatment. These conditions often lack approved therapies, leaving patients with limited or no treatment
Details: Drug development is no longer possible without considering children and the orphan indication and/or rare disease pediatric setting involves unique considerations in addition to the more common challenges…
Rare Diseases, Immunological Rare Diseases, Rare Diseases in Neurology, Rare Gynecological and Obstetrical Diseases, Orphan Drugs Potentiality. Dubai is leading city of United Arab Emirates, as well as famous city…
medicinal products intended for diagnosis, prevention or treatment of lifethreatening or debilitating rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market…
patient advocacy groups fighting against specific diseases. While this continues to be a driver, numerous recent trends indicate a thriving orphan drugs market with over 4000 orphan designations ... orphan drugs…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.